As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
ALX Oncology reports Q2 2025 results with a net loss of $25.9M, wider than expected, but shares dip only slightly. Clinical progress, including evorpacept data and ALX2004 trials, remains key focus. Cash reserves extend runway to Q1 2027.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
ALX Oncology announces Phase 2 ASPEN-06 trial results for evorpacept in combination with trastuzumab, Cyramza, and paclitaxel for HER2-positive gastric/GEJ cancer. The trial shows significant improvements in overall response rate and duration of response.
ALX Oncology's evorpacept, poised for pivotal HER2+ gastric cancer development. Caution prevails due to sub-$100 million market size; await additional plans backed by phase 1/2 data.
